# A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

> **NCT02913326** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 120 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** Dabigatran etexilate
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02913326
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-13
- **Primary completion:** 2018-06-22
- **Final completion:** 2018-06-22
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02913326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02913326, "A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02913326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*